TY - JOUR T1 - Living longer and living better: breast cancer endocrine therapy JF - BMJ Supportive & Palliative Care JO - BMJ Support Palliat Care SP - 361 LP - 362 DO - 10.1136/bmjspcare-2018-001666 VL - 9 IS - 3 AU - Paulo Luz AU - Beatriz Gosalbez Y1 - 2019/09/01 UR - http://spcare.bmj.com/content/9/3/361.abstract N2 - It was with great enthusiasm that we have seen the results published by Francis et al concerning the adjuvant hormone therapy. In the SOFT study (Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer), the 8-year disease-free survival rate was 78.9% in patients with only tamoxifen, 83.2% with tamoxifen and ovarian suppression and 85.9% with exemestane and ovarian suppression.1 The history of hormone therapy dates back more than a century (more precisely to 1896) when George Beatson, a British surgeon, describes surgical castration as a therapeutic option in some patients diagnosed with breast cancer.2 Until the late 1960s, this and the bilateral adrenalectomy were the only therapeutic options in hormone-sensitive disease. It was at this time that tamoxifen was discovered by Arthur … ER -